Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11287
Title: Melanoma vaccines: developments over the past 10 years.
Austin Authors: Klein, Oliver ;Schmidt, Christopher;Knights, Ashley J;Davis, Ian D;Chen, Weisan;Cebon, Jonathan S 
Affiliation: Ludwig Institute for Cancer Research, Austin Branch, Austin Hospital, Studley Road, Heidelberg, Victoria, 3084, Australia
Issue Date: 1-Jun-2011
Publication information: Expert Review of Vaccines; 10(6): 853-73
Abstract: Decades of preclinical evaluation and clinical trials into melanoma vaccines have yielded spectacular progress in our understanding of melanoma antigens and the immune mechanisms of tumor rejection. Key insights and the results of their clinical evaluation are reviewed in this article. Unfortunately, durable clinical benefit following vaccination remains uncommon. Two recent clinical advances that will impact on melanoma vaccine development are trials with inhibitors of CTLA-4 and oncogenic BRAF. Long-term therapeutic control of melanoma will require integration of specific active immunotherapy with these emerging successful therapies from the disparate fields of immune regulation and signal transduction.
Gov't Doc #: 21692705
URI: http://ahro.austin.org.au/austinjspui/handle/1/11287
DOI: 10.1586/erv.11.74
URL: https://pubmed.ncbi.nlm.nih.gov/21692705
Type: Journal Article
Subjects: Antigens, CD.immunology
CTLA-4 Antigen
Cancer Vaccines.administration & dosage.immunology
Clinical Trials as Topic
Humans
Melanoma.immunology.therapy
Proto-Oncogene Proteins B-raf.antagonists & inhibitors.immunology
Treatment Outcome
Appears in Collections:Journal articles

Show full item record

Page view(s)

12
checked on Dec 7, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.